Abstract
Therapy, and, therefore, prognosis, is strictly related to cancer stage, and hence, screening tests that can contribute to the early classification of disease stage represent a step forward in treatment. Unfortunately, few prognostic indices are available, especially noninvasive ones. Our study of the physiological network of the immune response, however, leads us to believe that it may well be possible to define immunological indices for the classification of cancer stage using blood parameters. In this paper, we show how the study of a patient's immune system can be used as a noninvasive tool for early-stage classification.
MeSH terms
-
CD3 Complex / blood
-
CD3 Complex / immunology
-
Carcinoembryonic Antigen / blood
-
Carcinoembryonic Antigen / immunology
-
Colonic Neoplasms / blood
-
Colonic Neoplasms / immunology*
-
Colonic Neoplasms / pathology*
-
Humans
-
Intercellular Adhesion Molecule-1 / blood
-
Intercellular Adhesion Molecule-1 / immunology
-
Interleukins / blood
-
Interleukins / immunology
-
Ki-1 Antigen / blood
-
Ki-1 Antigen / immunology
-
Matrix Metalloproteinase 1 / metabolism
-
Neoplasm Staging
-
Prognosis
-
Th1 Cells / immunology
-
Th2 Cells / immunology
-
Tissue Inhibitor of Metalloproteinase-1 / metabolism
-
Tumor Suppressor Protein p53 / blood
-
Tumor Suppressor Protein p53 / immunology
Substances
-
CD3 Complex
-
Carcinoembryonic Antigen
-
Interleukins
-
Ki-1 Antigen
-
Tissue Inhibitor of Metalloproteinase-1
-
Tumor Suppressor Protein p53
-
Intercellular Adhesion Molecule-1
-
Matrix Metalloproteinase 1